How should aminocaproic acid (Amicar) be used to manage bleeding in a child with von Willebrand disease?

Use of Aminocaproic Acid (Amicar) in Bleeding Management for Children with von Willebrand Disease

Aminocaproic acid (Amicar) should be used as an adjunctive antifibrinolytic agent in children with von Willebrand disease experiencing bleeding, particularly for mucosal bleeding, but only after primary hemostatic therapy with desmopressin (DDAVP) or von Willebrand factor concentrates has been initiated.

Primary Treatment Hierarchy

The management of bleeding in children with vWD follows a clear hierarchy where Amicar serves as an adjunct, not a primary therapy:

First-Line Therapy Based on vWD Type

For Type 1 vWD (most common, 70-80% of cases):

• DDAVP is the first-line treatment 1
• Dose: 0.3 μg/kg intravenously 2
• Promotes release of vWF and FVIII from endothelium 3
• Only effective if baseline vWF levels ≥10 IU/dL 4

For Type 2 vWD:

• Type 2A, 2M, 2N: Use vWF-containing factor concentrates (plasma-derived or recombinant) 1
• Type 2B: DDAVP is contraindicated due to risk of platelet clumping; use vWF concentrates instead 1

For Type 3 vWD (severe):

• Regular infusion of vWF/FVIII concentrates required 1
• Target levels >50 IU/dL for 5-7 days after procedures 1

Role of Aminocaproic Acid (Amicar)

When to Use Amicar

Aminocaproic acid plays an adjunctive role in specific bleeding scenarios:

Optimal indications:

• Mucosal bleeding (oral, nasal, menstrual) where fibrinolytic enzyme concentration is high 4
• Post-surgical bleeding, particularly adenotonsillar procedures 5, 4
• Postpartum hemorrhage prevention (given for 2 weeks after delivery) 1
• When used alongside DDAVP or vWF concentrates, not as monotherapy

Dosing and Duration

Extended dosing protocol (based on successful institutional experience):

• Oral aminocaproic acid administered for extended periods beyond the immediate perioperative window 5, 4
• Typically continued for 7-14 days post-procedure for high-risk mucosal surgeries 5
• For postpartum: 2 weeks or longer 1

Clinical Evidence

Research demonstrates effectiveness when used appropriately:

• In adenotonsillar procedures with vWD, protocols using DDAVP plus extended EACA showed no major bleeding in 13 children, though 23% had minor delayed bleeding 5
• Single-dose DDAVP combined with extended EACA in 6 pediatric patients was both well-tolerated and efficacious 4
• However, even with prophylaxis, bleeding rates remain 8-17% in some series 6, 7

Critical Safety Considerations

Important Caveats About Amicar Use

FDA labeling warnings 8:

• Should NOT be administered without definite diagnosis of hyperfibrinolysis
• May theoretically result in clotting or thrombosis
• Should not be given with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates due to increased thrombosis risk
• At high doses (>24 g/day IV), can prolong template bleeding time

Pediatric-specific concerns:

• Acute kidney injury (AKI) risk: EACA was associated with 3.3-fold increased odds of AKI in children with life-threatening hemorrhage (50% AKI rate vs 17.1% without antifibrinolytic) 9
• This AKI risk was significantly higher with EACA compared to tranexamic acid (TXA) 9
• Safety and effectiveness in pediatric patients have not been formally established by FDA 8

When NOT to Use Amicar

• As monotherapy without addressing underlying vWF deficiency
• In patients with DIC or active intravascular clotting
• Without confirming hyperfibrinolysis when possible
• In combination with prothrombin complex concentrates

Practical Clinical Algorithm

Step 1: Confirm vWD type and severity through laboratory testing (vWF antigen, vWF activity, FVIII levels)

Step 2: For active bleeding, initiate primary hemostatic therapy:

• Type 1 with vWF ≥10 IU/dL: DDAVP 0.3 μg/kg IV
• Type 2A, 2M, 2N, or Type 3: vWF concentrate (40-60 IU/kg)
• Type 2B: vWF concentrate only (never DDAVP)

Step 3: Add aminocaproic acid as adjunct for:

• Mucosal bleeding sites (oral, nasal, GI, menstrual)
• Post-surgical prophylaxis (especially adenotonsillar)
• Postpartum period (2 weeks minimum)

Step 4: Monitor for:

• Bleeding control within 24-48 hours
• Signs of thrombosis (rare but serious)
• Renal function if using extended courses
• Hyponatremia if using DDAVP (80% incidence) 5

Common Pitfalls to Avoid

1. Using Amicar alone: Always combine with DDAVP or vWF concentrates to address the underlying deficiency
2. Giving DDAVP in Type 2B: This causes dangerous platelet aggregation 1
3. Inadequate duration: Extended courses (7-14 days) are needed for mucosal procedures, not just perioperative dosing 5, 4
4. Ignoring renal function: Monitor for AKI, especially with prolonged use 9
5. Assuming all vWD is the same: Type-specific therapy is essential for safety and efficacy

The evidence consistently shows that Amicar enhances hemostasis when used appropriately as an adjunct to primary vWD-specific therapy, particularly for mucosal bleeding where fibrinolysis is prominent, but carries meaningful risks that require monitoring, especially regarding renal function in children.